Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Sunday, February 05, 2023

What's AGBT Like?

›
AGBT begins in less than 24 hours, and the signs are everywhere here at the Diplomat Resort in Hollywood Florida.  I arrived Friday with fam...
2 comments:
Tuesday, January 31, 2023

AGBT 2023 Is Nearly Upon Us!

›
AGBT is less than a week away in Hollywood Florida - and I've been letting everything else get ahead of writing anything here.  The JP M...
1 comment:
Tuesday, October 25, 2022

PacBio Revio: Same Footprint, 80% The Time, 15X The HiFi!

›
PacBio has been rolling out announcements around the ASHG meeting and now delivers a huge one: the next generation SMRT instrument “Revio” w...
5 comments:
Wednesday, October 19, 2022

Better Than FizzBuzz: First Bioinformatics Problem in an Erratic Series of Indeterminant Length

›
Periodically in my work or during writing this blog I come across computational problems that have the aspects of making, at least in my min...
2 comments:
Thursday, October 06, 2022

General Inception Aims to Ignite New Company Formation

›
A week ago, a company calling itself General Inception emerged from stealth as a new concept, which they call an “Igniter company”, to promo...
2 comments:
Wednesday, October 05, 2022

What Conversation Does Each Sequencing Instrument Vendor Wish You To Have?

›
6 comments:
Monday, October 03, 2022

Illumina Roadmap Part 2: Infinity Becomes Illumina Complete Long Reads

›
The Only Thing Clear About Infinity Is It Is Now Complete Long Reads.  Illumina told us a new name for Infinity -- Illumina Complete Long Re...
4 comments:
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.